ClinicalTrials.gg
Active, not recruitingNCT06161571Updated Apr 30, 2026

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase 3 interventional study of Efruxifermin and Placebo in NASH/MASH and NAFLD/MASLD, sponsored by Akero Therapeutics, Inc. Active, not recruiting at 211 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Akero Therapeutics, Inc (part of Novo Nordisk A/S) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.

Planned enrollment
3rd of 17
700 · median 71
Started
2023
with 5 others
Phase 3
3 of 18
1 open now
Registered
15th of 18
by date

Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 3, and was the 15th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.

03

Conditions studied

  • NASH/MASH
  • NAFLD/MASLD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main Study Only:

  • Males and non-pregnant, non-lactating females between 18 - 80 (between 19-80 in the Republic of Korea) years of age inclusive, on the day of signing
  • Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes
  • Suspected or confirmed diagnosis of NASH/MASH or NAFLD/MASLD or non-invasively diagnosed NASH/MASH or NAFLD/MASLD

Open-Label Rollover

  • Prior participation in a previous Akero Phase 2 study

Exclusion criteria

Exclusion Criteria:

  • Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results, including but not limited to: alcoholic liver disease, disorders (e.g., primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], autoimmune hepatitis), drug induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency
  • Type 1 or unstable Type 2 diabetes

A reduced list of inclusion and exclusion criteria apply to participants in the open-label rollover extension.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    EFX 50 mg

    Drug: Efruxifermin

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    EFX 50 mg (Open-Label Rollover)

    Drug: Efruxifermin

Interventions

  • Administered by subcutaneous (SC) injection

  • DrugPlacebo

    Administered by SC injection

06

What researchers measure

Primary outcomes

  1. Extent of exposure

    A participant's extent of exposure to study drug (weeks) will be generated from the data recorded in the study drug administration eCRF.

    Time frame: 52 Weeks

  2. Number of participants with adverse events

    An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to the study drug.

    Time frame: 52 Weeks

  3. Number of participants with adverse events by severity

    All AEs, both serious and non-serious, will be assessed for severity using the Common Terminology Criteria for Adverse Events v5.0.

    Time frame: 52 Weeks

  4. Number of participants with clinically significant changes in clinical assessments

    Clinical assessments include clinical laboratory tests, electrocardiogram, ultrasounds, vital sign assessments, and concomitant medication usage.

    Time frame: 52 Weeks

Secondary outcomes

  1. Percentage of participants with reduction in enhanced liver fibrosis (ELF) score by ≥ 0.5 and reduction in liver stiffness measurement (LSM) by ≥ 30%

    Time frame: 52 Weeks

  2. Change from baseline in non-invasive marker ELF score

    ELF scale of 6.7 to 9.8 where higher scores indicative of increased fibrosis.

    Time frame: 52 Weeks

  3. Change from baseline in non-invasive marker pro-peptide of type 3 procollagen (Pro-C3)

    Time frame: 52 Weeks

  4. Change from baseline in non-invasive marker liver stiffness assessed by transient elastography (kPa, CAP)

    Time frame: 52 Weeks

  5. Percentage of participants with a reduction in ELF score by ≥ 0.5

    Time frame: 52 Weeks

  6. Percentage of participants with a reduction in LSM by ≥ 30%

    Time frame: 52 Weeks

  7. Change from baseline in lipoproteins

    Total cholesterol (mg/dL), Triglycerides (TG) (mg/dL), high density lipoprotein cholesterol (HDL-C) (mg/dL), Non-HDL-C (mg/dL), and low-density lipoprotein cholesterol (LDL-C) (mg/dL).

    Time frame: 52 Weeks

  8. Change from baseline in markers of glycemic control: HbA1c (%)

    Time frame: 52 Weeks

  9. Change from baseline in markers of glycemic control: adiponectin (mg/L)

    Time frame: 52 Weeks

  10. Change from baseline in markers of liver injury

    Alanine aminotransferase (ALT) (U/L), aspartate aminotransferase (AST) (U/L), and gamma glutamyl transferase (GGT) (U/L).

    Time frame: 52 Weeks

  11. Change from baseline in markers of liver injury: uric acid (mg/dL)

    Time frame: 52 Weeks

  12. Change from baseline in body weight (kg)

    Time frame: 52 Weeks

07

Study locations

211 sites
  • Akero Clinical Study Site
    Birmingham, Alabama 35209, United States
  • Akero Clinical Study Site
    Chandler, Arizona 85224, United States
  • Akero Clinical Study Site
    Flagstaff, Arizona 86001, United States
  • Akero Clinical Study Site
    Peoria, Arizona 85381, United States
  • Akero Clinical Study Site
    Tucson, Arizona 85712, United States
  • Akero Clinical Study Site
    Tucson, Arizona 85715, United States
  • Akero Clinical Study Site
    Conway, Arkansas 72032, United States
  • Akero Clinical Study Site
    Jonesboro, Arkansas 72401, United States
  • Akero Clinical Study Site
    Little Rock, Arkansas 72205, United States
  • Akero Clinical Study Site
    North Little Rock, Arkansas 72117, United States
  • Akero Clinical Study Site
    Chula Vista, California 91910, United States
  • Akero Clinical Study Site
    Coronado, California 92118, United States
  • Akero Clinical Study Site
    Cypress, California 90630, United States
  • Akero Clinical Study Site
    Inglewood, California 90301, United States
  • Akero Clinical Study Site
    La Mesa, California 91942, United States
  • Akero Clinical Study Site
    Lancaster, California 93534, United States
  • Akero Clinical Study Site
    Los Angeles, California 90036-4669, United States
  • Akero Clinical Study Site
    Los Angeles, California 90057, United States
  • Akero Clinical Study Site
    Palm Springs, California 92262, United States
  • Akero Clinical Study Site
    San Diego, California 92120, United States
  • Akero Clinical Study Site
    San Diego, California 92123, United States
  • Akero Clinical Study Site
    San Francisco, California 94115, United States
  • Akero Clinical Study Site
    Santa Maria, California 93458, United States
  • Akero Clinical Study Site
    Englewood, Colorado 80113, United States
  • Akero Clinical Study Site
    Bradenton, Florida 34208, United States
  • Akero Clinical Study Site
    Brandon, Florida 33511, United States
  • Akero Clinical Study Site
    Fort Myers, Florida 33912, United States
  • Akero Clinical Study Site
    Gainesville, Florida 32610, United States
  • Akero Clinical Study Site
    Hialeah Gardens, Florida 33016, United States
  • Akero Clinical Study Site
    Inverness, Florida 34452, United States
  • Akero Clinical Study Site
    Jacksonville, Florida 32256, United States
  • Akero Clinical Study Site
    Lady Lake, Florida 32159, United States
  • Akero Clinical Study Site
    Lakewood Rch, Florida 34211, United States
  • Akero Clinical Study Site
    Largo, Florida 33777, United States
  • Akero Clinical Study Site
    Maitland, Florida 32751, United States
  • Akero Clinical Study Site
    Miami, Florida 33136, United States
  • Akero Clinical Study Site
    Miami Lakes, Florida 33016, United States
  • Akero Clinical Study Site
    Naples, Florida 34102, United States
  • Akero Clinical Study Site
    Ocala, Florida 34471, United States
  • Akero Clinical Study Site
    Port Orange, Florida 32127, United States
  • Akero Clinical Study Site
    Sarasota, Florida 34240, United States
  • Akero Clinical Study Site
    The Villages, Florida 32162, United States
  • Akero Clinical Study Site
    Venice, Florida 34285, United States
  • Akero Clinical Study Site
    Viera, Florida 32940, United States
  • Akero Clinical Study Site
    West Palm Beach, Florida 33401, United States
  • Akero Clinical Study Site
    Winter Park, Florida 32789, United States
  • Akero Clinical Study Site
    Winter Park, Florida 32792, United States
  • Akero Clinical Study Site
    Columbus, Georgia 31904, United States
  • Akero Clinical Study Site
    Gainesville, Georgia 30501, United States
  • Akero Clinical Study Site
    Marietta, Georgia 30060, United States
  • Akero Clinical Study Site
    South Bend, Indiana 46635, United States
  • Akero Clinical Study Site
    West Des Moines, Iowa 50265, United States
  • Akero Clinical Study Site
    Topeka, Kansas 66606, United States
  • Akero Clinical Study Site
    Wichita, Kansas 67205, United States
  • Akero Clinical Study Site
    Bastrop, Louisiana 71220, United States
  • Akero Clinical Study Site
    Covington, Louisiana 70433, United States
  • Akero Clinical Study Site
    Houma, Louisiana 70363, United States
  • Akero Clinical Study Site
    Marrero, Louisiana 70072, United States
  • Akero Clinical Study Site
    Metairie, Louisiana 70006, United States
  • Akero Clinical Study Site
    New Orleans, Louisiana 70121, United States
  • Akero Clinical Study Site
    Shreveport, Louisiana 71103, United States
  • Akero Clinical Study Site
    Baltimore, Maryland 21202, United States
  • Akero Clinical Study Site
    Glen Burnie, Maryland 21061, United States
  • Akero Clinical Study Site
    Greenbelt, Maryland 20770, United States
  • Akero Clinical Study Site
    South Dartmouth, Massachusetts 02747, United States
  • Akero Clinical Study Site
    Southfield, Michigan 48075, United States
  • Akero Clinical Study Site
    Wyoming, Michigan 49519, United States
  • Akero Clinical Study Site
    Ypsilanti, Michigan 48197, United States
  • Akero Clinical Study Site
    Columbia, Missouri 65201, United States
  • Akero Clinical Study Site
    Kansas City, Missouri 64131, United States
  • Akero Clinical Study Site
    Las Vegas, Nevada 89106, United States
  • Akero Clinical Study Site
    Las Vegas, Nevada 89109, United States
  • Akero Clinical Study Site
    Reno, Nevada 89511, United States
  • Akero Clinical Study Site
    Brick, New Jersey 08724, United States
  • Akero Clinical Study Site
    Florham Park, New Jersey 07932, United States
  • Akero Clinical Study Site
    Somers Point, New Jersey 08244, United States
  • Akero Clinical Study Site
    Sparta, New Jersey 07871, United States
  • Akero Clinical Study Site
    Santa Fe, New Mexico 87505, United States
  • Akero Clinical Study Site
    New York, New York 10029, United States
  • Akero Clinical Study Site
    New York, New York 10033, United States
  • Akero Clinical Study Site
    Chapel Hill, North Carolina 27516, United States
  • Akero Clinical Study Site
    Charlotte, North Carolina 28204, United States
  • Akero Clinical Study Site
    Fayetteville, North Carolina 28304, United States
  • Akero Clinical Study Site
    Morehead City, North Carolina 28557, United States
  • Akero Clinical Study Site
    New Bern, North Carolina 28562, United States
  • Akero Clinical Study Site
    Raleigh, North Carolina 27612, United States
  • Akero Clinical Study Site
    Statesville, North Carolina 28625, United States
  • Akero Clinical Study Site
    Columbus, Ohio 43213, United States
  • Akero Clinical Study Site
    Dayton, Ohio 45414, United States
  • Akero Clinical Study Site
    Springboro, Ohio 45066, United States
  • Akero Clinical Study Site
    Westlake, Ohio 44145, United States
  • Akero Clinical Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Akero Clinical Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Akero Clinical Study Site
    Pittsburgh, Pennsylvania 15213, United States
  • Akero Clinical Study Site
    Columbia, South Carolina 29204, United States
  • Akero Clinical Study Site
    Summerville, South Carolina 29485, United States
  • Akero Clinical Study Site
    Chattanooga, Tennessee 37421, United States
  • Akero Clinical Study Site
    Clarksville, Tennessee 37040, United States
  • Akero Clinical Study Site
    Hermitage, Tennessee 37076, United States
  • Akero Clinical Study Site
    Nashville, Tennessee 37211, United States

Showing the first 100 of 211 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2026, 27 months.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 8, 2023
StartActual
Nov 10, 2023
Primary completionActual
Mar 3, 2026
CompletionEst.
Jun 19, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06161571
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Nov 10, 2023
Primary completion
Mar 3, 2026
Completion
Jun 19, 2026 (estimated)
Last update
Apr 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efruxifermin

Start the discussion